ABBV-438
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 01, 2026
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
(clinicaltrials.gov)
- P1 | N=127 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting
Adverse events • Enrollment open • First-in-human • Hematological Malignancies • Multiple Myeloma • Oncology
February 14, 2026
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
(clinicaltrials.gov)
- P1 | N=127 | Not yet recruiting | Sponsor: AbbVie
Adverse events • First-in-human • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 2
Of
2
Go to page
1